{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:37Z","timestamp":1794047377843,"version":"4.8.0"},"reference-count":58,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Terminal sialylation determines the plasma half-life of von Willebrand factor (VWF). A role for macrophage galactose lectin (MGL) in regulating hyposialylated VWF clearance has recently been proposed. In this study, we showed that MGL influences physiological plasma VWF clearance. MGL inhibition was associated with a significantly extended mean residence time and 3-fold increase in endogenous plasma VWF antigen levels (P&lt;0.05). Using a series of VWF truncations, we further demonstrated that the A1 domain of VWF is predominantly responsible for enabling the MGL interaction. Binding of both full-length and VWF-A1-A2-A3 to MGL was significantly enhanced in the presence of ristocetin (P&lt;0.05), suggesting that the MGL-binding site in A1 is not fully accessible in globular VWF. Additional studies using different VWF glycoforms demonstrated that VWF O-linked glycans, clustered at either end of the A1 domain, play a key role in protecting VWF against MGLmediated clearance. Reduced sialylation has been associated with pathological, increased clearance of VWF in patients with von Willebrand disease. Herein, we demonstrate that specific loss of \u03b12-3 linked sialylation from O-glycans results in markedly increased MGL-binding in vitro, and markedly enhanced MGL-mediated clearance of VWF in vivo. Our data further show that the asialoglycoprotein receptor (ASGPR) does not have a significant role in mediating the increased clearance of VWF following loss of O-sialylation. Conversely however, we observed that loss of N-linked sialylation from VWF drives enhanced circulatory clearance predominantly via the ASGPR. Collectively, our data support the hypothesis that in addition to regulating physiological VWF clearance, the MGL receptor works in tandem with ASGPR to modulate enhanced clearance of aberrantly sialylated VWF in the pathogenesis of von Willebrand disease.<\/jats:p>","DOI":"10.3324\/haematol.2020.274720","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T14:48:08Z","timestamp":1616683688000},"page":"668-679","source":"Crossref","is-referenced-by-count":23,"title":["Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance"],"prefix":"10.3324","volume":"107","author":[{"given":"Soracha E.","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie M.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan B.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I. R.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotika","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judicael","family":"Fazavana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Monopoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.J.","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Chion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Haberichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"33821","doi-asserted-by":"crossref","unstructured":"Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015; 125(13):2019-2028.","DOI":"10.1182\/blood-2014-06-528406"},{"key":"33822","doi-asserted-by":"crossref","unstructured":"Leebeek FWG, Eikenboom JCJ. von Willebrand's disease. N Engl J Med. 2017; 376(7):701-702.","DOI":"10.1056\/NEJMc1616060"},{"key":"33823","doi-asserted-by":"crossref","unstructured":"O'Sullivan JM, Ward S, Lavin M, O'Donnell JS. von Willebrand factor clearance - biological mechanisms and clinical significance. Br J Haematol. 2018; 183(2):185-195.","DOI":"10.1111\/bjh.15565"},{"key":"33824","doi-asserted-by":"crossref","unstructured":"Castaman G, Lethagen S, Federici AB. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008; 111(7):3531-3539.","DOI":"10.1182\/blood-2007-08-109231"},{"key":"33825","doi-asserted-by":"crossref","unstructured":"Flood VH, Christopherson PA, Gill JC. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood. 2016; 127(20):2481-2488.","DOI":"10.1182\/blood-2015-10-673681"},{"key":"33826","doi-asserted-by":"crossref","unstructured":"Eikenboom J, Federici AB, Dirven RJ. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013; 121(12):2336-2339.","DOI":"10.1182\/blood-2012-09-455089"},{"key":"33827","doi-asserted-by":"crossref","unstructured":"Sanders YV, Groeneveld D, Meijer K. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood. 2015; 125(19):3006-3013.","DOI":"10.1182\/blood-2014-09-603241"},{"key":"33828","doi-asserted-by":"crossref","unstructured":"Haberichter SL, Castaman G, Budde U. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM- 1VWD). Blood. 2008; 111(10):4979-4985.","DOI":"10.1182\/blood-2007-09-110940"},{"key":"33829","doi-asserted-by":"crossref","unstructured":"Lavin M, Aguila S, Schneppenheim S. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017; 130(21):2344-2353.","DOI":"10.1182\/blood-2017-05-786699"},{"key":"33830","doi-asserted-by":"crossref","unstructured":"Aguila S, Lavin M, Dalton N. Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood. 2019; 133(14):1585-1596.","DOI":"10.1182\/blood-2018-09-874636"},{"key":"33831","doi-asserted-by":"crossref","unstructured":"Casari C, Du V, Wu YP. Accelerated uptake of VWF\/platelet complexes in macrophages contributes to VWD type 2Bassociated thrombocytopenia. Blood. 2013; 122(16):2893-2902.","DOI":"10.1182\/blood-2013-03-493312"},{"key":"33832","doi-asserted-by":"crossref","unstructured":"O'Donnell JS. Low VWF: insights into pathogenesis, diagnosis, and clinical management. Blood Adv. 2020; 4(13):3191-3199.","DOI":"10.1182\/bloodadvances.2020002038"},{"key":"33833","doi-asserted-by":"crossref","unstructured":"Lenting PJ, Westein E, Terraube V. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem. 2004; 279(13):12102-12109.","DOI":"10.1074\/jbc.M310436200"},{"key":"33834","doi-asserted-by":"crossref","unstructured":"van Schooten CJ, Shahbazi S, Groot E. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood. 2008; 112(5):1704-1712.","DOI":"10.1182\/blood-2008-01-133181"},{"key":"33835","doi-asserted-by":"crossref","unstructured":"Rawley O, O'Sullivan JM, Chion A. von Willebrand factor arginine 1205 substitution results in accelerated macrophagedependent clearance in vivo. J Thromb Haemost. 2015; 13(5):821-826.","DOI":"10.1111\/jth.12875"},{"key":"33836","doi-asserted-by":"crossref","unstructured":"Chion A, O'Sullivan JM, Drakeford C. N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. Blood. 2016; 128(15):1959-1968.","DOI":"10.1182\/blood-2016-04-709436"},{"key":"33837","doi-asserted-by":"crossref","unstructured":"Swystun LL, Lai JD, Notley C. The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. J Clin Invest. 2018; 128(9):4057-4073.","DOI":"10.1172\/JCI96400"},{"key":"33838","doi-asserted-by":"crossref","unstructured":"Pegon JN, Kurdi M, Casari C. Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica. 2012; 97(12):1855-1863.","DOI":"10.3324\/haematol.2012.063297"},{"key":"33839","doi-asserted-by":"crossref","unstructured":"Rastegarlari G, Pegon JN, Casari C. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood. 2012; 119(9):2126-2134.","DOI":"10.1182\/blood-2011-08-373605"},{"key":"33840","doi-asserted-by":"crossref","unstructured":"Wohner N, Muczynski V, Mohamadi A. Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor. Haematologica. 2018; 103(4):728-737.","DOI":"10.3324\/haematol.2017.175216"},{"key":"33841","doi-asserted-by":"crossref","unstructured":"Ward SE, O'Sullivan JM, Drakeford C. A novel role for the macrophage galactosetype lectin receptor in mediating von Willebrand factor clearance. Blood. 2018; 131(8):911-916.","DOI":"10.1182\/blood-2017-06-787853"},{"key":"33842","doi-asserted-by":"crossref","unstructured":"Rydz N, Swystun LL, Notley C. The Ctype lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood. 2013; 121(26):5228-5237.","DOI":"10.1182\/blood-2012-10-457507"},{"key":"33843","doi-asserted-by":"crossref","unstructured":"Swystun LL, Ogiwara K, Lai JD. The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen. J Thromb Haemost. 2019; 17(8):1384-1396.","DOI":"10.1111\/jth.14521"},{"key":"33844","doi-asserted-by":"crossref","unstructured":"Grewal PK, Uchiyama S, Ditto D. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008; 14(6):648-655.","DOI":"10.1038\/nm1760"},{"key":"33845","doi-asserted-by":"crossref","unstructured":"Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV. Clearance of von Willebrand factor. J Thromb Haemost. 2013; 11(Suppl 1):202-211.","DOI":"10.1111\/jth.12226"},{"key":"33846","doi-asserted-by":"crossref","unstructured":"Casonato A, Pontara E, Sartorello F. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood. 2002; 99(1):180-184.","DOI":"10.1182\/blood.V99.1.180"},{"key":"33847","doi-asserted-by":"crossref","unstructured":"Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII\/von Willebrand factor protein. J Biol Chem. 1977; 252(15):5538-5546.","DOI":"10.1016\/S0021-9258(19)63384-3"},{"key":"33848","doi-asserted-by":"crossref","unstructured":"Stoddart JH, Andersen J, Lynch DC. Clearance of normal and type 2A von Willebrand factor in the rat. Blood. 1996; 88(5):1692-1699.","DOI":"10.1182\/blood.V88.5.1692.1692"},{"key":"33849","doi-asserted-by":"crossref","unstructured":"O'Sullivan JM, Aguila S, McRae E. Nlinked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor. J Thromb Haemost. 2016; 14(12):2446-2457.","DOI":"10.1111\/jth.13537"},{"key":"33850","doi-asserted-by":"crossref","unstructured":"Preston RJ, Rawley O, Gleeson EM, O'Donnell JS. Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities. Blood. 2013; 121(19):3801-3810.","DOI":"10.1182\/blood-2012-10-415000"},{"key":"33851","doi-asserted-by":"crossref","unstructured":"Gallinaro L, Cattini MG, Sztukowska M. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008; 111(7):3540-3545.","DOI":"10.1182\/blood-2007-11-122945"},{"key":"33852","doi-asserted-by":"crossref","unstructured":"Ward SE, O'Sullivan JM, O'Donnell JS. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood. 2020; 136(25):2864-2874.","DOI":"10.1182\/blood.2020005843"},{"key":"33853","doi-asserted-by":"crossref","unstructured":"Ellies LG, Ditto D, Levy GG. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci U S A. 2002; 99(15):10042-10047.","DOI":"10.1073\/pnas.142005099"},{"key":"33854","doi-asserted-by":"crossref","unstructured":"Canis K, McKinnon TA, Nowak A. Mapping the N-glycome of human von Willebrand factor. Biochem J. 2012; 447(2):217-228.","DOI":"10.1042\/BJ20120810"},{"key":"33855","doi-asserted-by":"crossref","unstructured":"Canis K, McKinnon TA, Nowak A. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost. 2010; 8(1):137-145.","DOI":"10.1111\/j.1538-7836.2009.03665.x"},{"key":"33856","doi-asserted-by":"crossref","unstructured":"Solecka BA, Weise C, Laffan MA, Kannicht C. Site-specific analysis of von Willebrand factor O-glycosylation. J Thromb Haemost. 2016; 14(4):733-746.","DOI":"10.1111\/jth.13260"},{"key":"33857","doi-asserted-by":"crossref","unstructured":"Gashash EA, Aloor A, Li D. An Insight into glyco-microheterogeneity of plasma von Willebrand factor by mass spectrometry. J Proteome Res. 2017; 16(9):3348-3362.","DOI":"10.1021\/acs.jproteome.7b00359"},{"key":"33858","doi-asserted-by":"crossref","unstructured":"Yang WH, Aziz PV, Heithoff DM, Mahan MJ, Smith JW, Marth JD. An intrinsic mechanism of secreted protein aging and turnover. Proc Natl Acad Sci U S A. 2015; 112(44):13657-13662.","DOI":"10.1073\/pnas.1515464112"},{"key":"33859","doi-asserted-by":"crossref","unstructured":"Lopes AA, Ferraz de Souza B, Maeda NY. Decreased sialic acid content of plasma von Willebrand factor in precapillary pulmonary hypertension. Thromb Haemost. 2000; 83(5):683-687.","DOI":"10.1055\/s-0037-1613892"},{"key":"33860","doi-asserted-by":"crossref","unstructured":"van Schooten CJ, Denis CV, Lisman T. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood. 2007; 109(6):2430-2437.","DOI":"10.1182\/blood-2006-06-032706"},{"key":"33861","doi-asserted-by":"crossref","unstructured":"Ward S, O'Sullivan JM, O'Donnell JS. von Willebrand factor sialylation-A critical regulator of biological function. J Thromb Haemost. 2019; 17(7):1018-1029.","DOI":"10.1111\/jth.14471"},{"key":"33862","doi-asserted-by":"crossref","unstructured":"Millar CM, Riddell AF, Brown SA. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost. 2008; 99(5):916-924.","DOI":"10.1160\/TH07-09-0565"},{"key":"33863","doi-asserted-by":"crossref","unstructured":"McGrath RT, van den Biggelaar M, Byrne B. Altered glycosylation of plateletderived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood. 2013; 122(25):4107-4110.","DOI":"10.1182\/blood-2013-04-496851"},{"key":"33864","doi-asserted-by":"crossref","unstructured":"McGrath RT, McKinnon TA, Byrne B. Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood. 2010; 115(13):2666-2673.","DOI":"10.1182\/blood-2009-09-241547"},{"key":"33865","doi-asserted-by":"crossref","unstructured":"Tsuiji M, Fujimori M, Ohashi Y. Molecular cloning and characterization of a novel mouse macrophage C-type lectin, mMGL2, which has a distinct carbohydrate specificity from mMGL1. J Biol Chem. 2002; 277(32):28892-28901.","DOI":"10.1074\/jbc.M203774200"},{"key":"33866","doi-asserted-by":"crossref","unstructured":"Wohner N, Legendre P, Casari C, Christophe OD, Lenting PJ, Denis CV. Shear stress-independent binding of von Willebrand factortype 2B mutants p.R1306Q &amp; p.V1316M to LRP1 explains their increased clearance. J Thromb Haemost. 2015; 13(5):815-820.","DOI":"10.1111\/jth.12885"},{"key":"33867","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci U S A. 1995; 92(7):2428-2432.","DOI":"10.1073\/pnas.92.7.2428"},{"key":"33868","doi-asserted-by":"crossref","unstructured":"McGrath RT, McRae E, Smith OP, O'Donnell JS. Platelet von Willebrand factor-- structure, function and biological importance. Br J Haematol. 2010; 148(6):834-843.","DOI":"10.1111\/j.1365-2141.2009.08052.x"},{"key":"33869","doi-asserted-by":"crossref","unstructured":"Williams SB, McKeown LP, Krutzsch H, Hansmann K, Gralnick HR. Purification and characterization of human platelet von Willebrand factor. Br J Haematol. 1994; 88(3):582-591.","DOI":"10.1111\/j.1365-2141.1994.tb05077.x"},{"key":"33870","doi-asserted-by":"crossref","unstructured":"Brown SA, Collins PW, Bowen DJ. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost. 2002; 87(6):990-996.","DOI":"10.1055\/s-0037-1613123"},{"key":"33871","doi-asserted-by":"crossref","unstructured":"Lenting PJ, Pegon JN, Christophe OD, Denis CV. Factor VIII and von Willebrand factor-- too sweet for their own good. Haemophilia. 2010; 16(Suppl 5):194-199.","DOI":"10.1111\/j.1365-2516.2010.02320.x"},{"key":"33872","doi-asserted-by":"crossref","unstructured":"Tischer A, Machha VR, Moon-Tasson L, Benson LM, Auton M. Glycosylation sterically inhibits platelet adhesion to von Willebrand factor without altering intrinsic conformational dynamics. J Thromb Haemost. 2020; 18(1):79-90.","DOI":"10.1111\/jth.14628"},{"key":"33873","doi-asserted-by":"crossref","unstructured":"Deng W, Wang Y, Druzak SA. A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor. J Thromb Haemost. 2017; 15(9):1867-1877.","DOI":"10.1111\/jth.13775"},{"key":"33874","doi-asserted-by":"crossref","unstructured":"Soong G, Muir A, Gomez MI. Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. J Clin Invest. 2006; 116(8):2297-2305.","DOI":"10.1172\/JCI27920"},{"key":"33875","doi-asserted-by":"crossref","unstructured":"Badirou I, Kurdi M, Legendre P. In vivo analysis of the role of O-glycosylations of von Willebrand factor. PLoS One. 2012; 7(5):e37508.","DOI":"10.1371\/journal.pone.0037508"},{"key":"33876","doi-asserted-by":"crossref","unstructured":"Saint-Lu N, Oortwijn BD, Pegon JN. Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor. Arterioscler Thromb Vasc Biol. 2012; 32(4):894-901.","DOI":"10.1161\/ATVBAHA.111.240309"},{"key":"33877","doi-asserted-by":"crossref","unstructured":"O'Sullivan JM, Jenkins PV, Rawley O. Galectin-1 and galectin-3 constitute novelbinding partners for factor VIII. Arterioscler Thromb Vasc Biol. 2016; 36(5):855-863.","DOI":"10.1161\/ATVBAHA.115.306915"},{"key":"33878","doi-asserted-by":"crossref","unstructured":"Deppermann C, Kratofil RM, Peiseler M. Macrophage galactose lectin is critical for Kupffer cells to clear aged platelets. J Exp Med. 2020; 217(4):e20190723.","DOI":"10.1084\/jem.20190723"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2020.274720\/73130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2020.274720\/74193","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10217\/73130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:59:19Z","timestamp":1794045559000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2020.274720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.274720","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,25]]}}}